Skip to main content
SpringerLink
Log in

High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aiba M, Shigematsu A, Suzuki T, Miyagishima T (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. https://doi.org/10.1007/s00277-023-05102-y

    Article  PubMed  PubMed Central  Google Scholar 

  2. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629

    Article  CAS  PubMed  Google Scholar 

  3. Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I (2022) Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol 52(1):29–38

    Article  PubMed  Google Scholar 

  4. Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3(20):2911–2919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW (2022) Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6(13):3997–4005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, JR Tokyo General Hospital, 2-1-3, Yoyogi, Shibuya-Ku, Tokyo, 151-8528, Japan

    Kensuke Matsuda & Koichi Sugimoto

  2. Department of Pharmacy, JR Tokyo General Hospital, 2-1-3, Yoyogi, Shibuya-Ku, Tokyo, 151-8528, Japan

    Takashi Yoshida

Authors
  1. Kensuke Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koichi Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KM, TY, and KS review the article. KM wrote the manuscript. All authors revised the manuscript and approved the final manuscript.

Corresponding author

Correspondence to Kensuke Matsuda.

Ethics declarations

Ethical approval

This study did not include any patient data. Thus, this study did not apply to the Declaration of Helsinki.

Conflict of interest

KM received a lecture fee from Abbvie, which was not related to the current study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsuda, K., Yoshida, T. & Sugimoto, K. High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia. Ann Hematol 102, 971–972 (2023). https://doi.org/10.1007/s00277-023-05143-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05143-3

Search

Navigation